Zentalis Pharmaceuticals, Inc.
ZNTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001725160
In the last 90 days, Zentalis Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 114 institutions reported holding it in 13F filings for Q2 2026, worth $228.9M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Zentalis Pharmaceuticals, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 106
- −15 vs. Q3 2022
- Shares held
- 64.3M
- +5.55M (+9.4%) vs. Q3 2022
- Total value
- $1.30B
- +$22.3M (+1.7%) vs. Q3 2022
- New holders
- 6
- 49 more added
- Sold out
- 21
- 29 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ZNTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 114 | $228.9M |
| Q1 2026 | 102 | $101.7M |
| Q4 2025 | 86 | $54.9M |
| Q3 2025 | 99 | $79.7M |
| Q2 2025 | 117 | $64.5M |
| Q1 2025 | 132 | $92.9M |
| Q4 2024 | 142 | $195.2M |
| Q3 2024 | 136 | $261.2M |
| Q2 2024 | 145 | $314.3M |
| Q1 2024 | 142 | $1.34B |
| Q4 2023 | 120 | $1.23B |
| Q3 2023 | 137 | $1.61B |
| Q2 2023 | 134 | $2.32B |
| Q1 2023 | 110 | $1.15B |
| Q4 2022 | 106 | $1.30B |
| Q3 2022 | 121 | $1.27B |
| Q2 2022 | 122 | $1.64B |
| Q1 2022 | 128 | $2.05B |
| Q4 2021 | 139 | $3.61B |
| Q3 2021 | 116 | $2.75B |
| Q2 2021 | 120 | $2.13B |
| Q1 2021 | 95 | $1.58B |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Zentalis Pharmaceuticals, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock Inc. | 3,472,179 | $69.9M | 0.00% | +136,113+4.1% | Added |
| Wellington Management Group LLP | 3,618,493 | $72.9M | 0.01% | +496,129+15.9% | Added |
| Vanguard Group Inc | 4,160,149 | $83.8M | 0.00% | +53,888+1.3% | Added |
| Avidity Partners Management LP | 5,150,000 | $103.7M | 2.42% | +926,900+21.9% | Added |
| FMR LLC | 7,909,176 | $159.3M | 0.02% | +339,570+4.5% | Added |
| Matrix Capital Management Company, LP | 9,199,973 | $185.3M | 3.54% | 00.0% | Unchanged |
| Polar Capital Holdings Plc | 0 | $0 | 0.00% | −377,728−100.0% | Sold out |
| AXA S.A. | 0 | $0 | 0.00% | −228,827−100.0% | Sold out |
| Affinity Asset Advisors, LLC | 0 | $0 | 0.00% | −170,000−100.0% | Sold out |
| Nicholas Investment Partners, LP | 0 | $0 | 0.00% | −158,704−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −85,529−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −76,564−100.0% | Sold out |
| SEI Investments Co | 0 | $0 | 0.00% | −74,192−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −72,768−100.0% | Sold out |
| Canada Pension Plan Investment Board | 0 | $0 | 0.00% | −36,500−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −29,269−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −29,112−100.0% | Sold out |
| Twinbeech Capital LP | 0 | $0 | 0.00% | −28,027−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −22,600−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −14,348−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −13,527−100.0% | Sold out |
| Cna Financial Corp | 0 | $0 | 0.00% | −10,516−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −9,655−100.0% | Sold out |
| Acuta Capital Partners, LLC | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −2,740−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −1,382−100.0% | Sold out |
| Macquarie Group Ltd | 0 | $0 | 0.00% | 0 | Sold out |